Search
Search Results
-
Combining gene expression analysis of gastric cancer cell lines and tumor specimens to identify biomarkers for anti-HER therapies—the role of HAS2, SHB and HBEGF
BackgroundThe standard treatment for patients with advanced HER2-positive gastric cancer is a combination of the antibody trastuzumab and...
-
LncSNHG14 promotes nutlin3a resistance by inhibiting ferroptosis via the miR-206 /SLC7A11 axis in osteosarcoma cells
The most prevalent form of primary osseous malignant tumor in adolescents and children is osteosarcoma (OS). A combination of surgery and...
-
Targeting HER2-positive breast cancer: advances and future directions
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly...
-
The PPP2R1A cancer hotspot mutant p.R183W increases clofarabine resistance in uterine serous carcinoma cells by a gain-of-function mechanism
PurposeUterine serous carcinoma (USC) is generally associated with poor prognosis due to a high recurrence rate and frequent treatment resistance;...
-
Retraction Note to: Activation of LncRNA TINCR by H3K27 acetylation promotes Trastuzumab resistance and epithelial-mesenchymal transition by targeting MicroRNA-125b in breast Cancer
This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s12943-018-0931-9.
-
Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917)
BackgroundTrastuzumab emtansine (T-DM1) is a second-line standard therapy for patients with human epidermal growth factor receptor 2 (HER2)-positive...
-
Biosimilars in Gastric Cancer
Gastric cancer, often known as GC, continues to be one of the most common forms of cancer in the world. Its toll in 2020 exceeded one million new...
-
Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer
BackgroundAcquired resistance to trastuzumab is a major clinical problem in the treatment of HER2-positive (HER2+) breast cancer patients. The...
-
Current Updates on Trastuzumab Resistance in HER2 Overexpressing Breast Cancers
Trastuzumab represents the predominant therapy to target breast cancer subtype marked by HER2 amplification. It has been in use for two decades and...
-
Emerging Paradigm of Breast Cancer Resistance and Treatment
We are at earlier stages of develo** methods to use liquid biopsy, machine learning, and artificial intelligence for the betterment of patients....
-
Biosimilars in Breast Cancer
Breast cancer is a significant health concern globally, leading to maximum mortalities amongst women worldwide, which is 11.6% of all cancers...
-
Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies
Cetuximab and panitumumab are monoclonal antibodies (mAbs) against epidermal growth factor receptor (EGFR) that are effective agents for metastatic...
-
Bridging The Age Gap: observational cohort study of effects of chemotherapy and trastuzumab on recurrence, survival and quality of life in older women with early breast cancer
BackgroundChemotherapy improves outcomes for high risk early breast cancer (EBC) patients but is infrequently offered to older individuals. This...
-
Transcriptome Profiling Analysis Identifies LCP1 as a Contributor for Chidamide Resistance in Gastric Cancer
BackgroundGastric cancer (GC) remains a significant health problem and carries with it substantial morbidity and mortality. Chidamide is a novel and...
-
Recent Development of Monoclonal Antibodies Targeting Tyrosine Kinase in ROS-Mediated Cancer
The past decade has witnessed the growth in development of monoclonal antibodies (mAbs) and its curative activity towards cancer and tumor producing...
-
RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer
BackgroundAround 15–20% of primary breast cancers are characterized by HER2 protein overexpression and/or HER2 gene amplification. Despite the...
-
A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer
BackgroundGastric cancer (GC) is one of the leading causes of cancer-related deaths worldwide. Human epidermal growth factor receptor 2 (HER2)...
-
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
BackgroundIncreasing data indicate that HER2-positive (HER2 + ) breast cancer (BC) subtypes exhibit differential responses to targeted anti-HER2...
-
Pulsed-laser irradiation of multifunctional gold nanoshells to overcome trastuzumab resistance in HER2-overexpressing breast cancer
BackgroundHER2-overexpressing metastatic breast cancers are challenging practice in oncology when they become resistant to anti-HER2 therapies such...
-
Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
BackgroundTrastuzumab is a drug that targets the receptor tyrosine kinase HER2 and is essential for the treatment of HER2-positive breast cancer....
